Chronic hepatitis B: Whom to treat and for how long? Propositions, challenges, and future directions

Sang Hoon Ahn, Henry L.Y. Chan, Pei Jer Chen, Jun Cheng, Mahesh K. Goenka, Jinlin Hou, Seng Gee Lim, Masao Omata, Teerha Piratvisuth, Qing Xie, Hyung Joon Yim, Man Fung Yuen

Research output: Contribution to journalReview articlepeer-review

30 Citations (Scopus)


Recent guidelines of the American Association for the Study of Liver Diseases, the European Association for the Study of the Liver, and the Asian Pacific Association for the Study of the Liver 2008 update of the "Asian-Pacific consensus statement on the management of chronic hepatitis B" offer comprehensive recommendations for the general management of chronic hepatitis B (CHB). These recommendations highlight preferred approaches to the prevention, diagnosis, and treatment of CHB. Nonetheless, the results of recent studies have led to an improved understanding of the disease and a belief that current recommendations on specific therapeutic considerations, including CHB treatment initiation and cessation criteria, particularly in patient populations with special circumstances, can be improved. Twelve experts from the Asia-Pacific region formed the Asia-Pacific Panel Recommendations for the Optimal Management of Chronic Hepatitis B (APPROACH) Working Group to review, challenge, and assess relevant new data and inform future updates of CHB treatment guidelines. The significance of and controversy about reported findings were discussed and debated in an expert meeting of the Working Group in Beijing, China, in November 2008. This review paper attempts to identify areas requiring improved CHB management and provide suggestions for future guideline updates, with special emphasis on treatment initiation and duration.

Original languageEnglish
Pages (from-to)386-395
Number of pages10
JournalHepatology International
Issue number1
Publication statusPublished - 2010 Mar

All Science Journal Classification (ASJC) codes

  • Hepatology


Dive into the research topics of 'Chronic hepatitis B: Whom to treat and for how long? Propositions, challenges, and future directions'. Together they form a unique fingerprint.

Cite this